大疱性表皮松解症
单纯大疱性表皮松解
遗传咨询
医学
队列
外显子组测序
基因检测
遗传异质性
外显子组
人口
遗传诊断
遗传学
皮肤病科
生物
病理
基因
内科学
突变
表型
环境卫生
作者
Vanessa Ota,Luiza Monteavaro Mariath,Rosalie Matuk Fuentes Torrelio,Carolina Sayuri Arashiro,Lavínia Schüler‐Faccini,J. Fernandes,Leandro Leitoguinho Rossi,Jeanine Aparecida Magno,Priscila Keiko Matsumoto Martin
摘要
BACKGROUND: Epidermolysis bullosa (EB) comprises a diverse group of rare genetic skin fragility disorders. Accurate diagnosis and genetic counselling require genetic analysis. To our knowledge, this is the largest genetic study of EB in Brazil and one of the largest worldwide. OBJECTIVES: To characterize the genetic basis of EB in a large, diverse cohort and provide a comprehensive overview of the mutational landscape in this population. METHODS: Whole-exome sequencing was performed on 393 individuals from 349 families with a clinical or suspected diagnosis of EB. RESULTS: A definitive EB diagnosis or differential diagnosis was achieved in 91.6% (n = 360/393) of our sample, including 1 case of peeling skin syndrome 2. We identified 211 pathogenic or likely pathogenic variants in 12 genes, including 63 novel variants. Dystrophic EB was the most prevalent type (n = 266/359, 74.1%), with 149 variants identified (46 novel). The most frequent variant was the COL7A1 c.6527_6528insC. EB simplex accounted for 18.7% of cases (n = 67/359), with 36 variants identified (9 novel). The most frequent variants affected residue 125 of KRT14. Junctional EB comprised 6.7% of cases (n = 24/359), with 22 variants (8 novel) identified. The LAMB3 c.31dup variant was the most prevalent. Kindler EB was diagnosed in 0.6% of the patients (n = 2/359), and 4 variants were identified. For 164 of the 359 individuals (45.7%), the initial clinical diagnosis differed from the genetically confirmed EB type, highlighting the importance of genetic diagnosis. CONCLUSIONS: This study provides a comprehensive genetic overview of EB in Brazil, highlighting EB type prevalence and novel variants. This knowledge is crucial for genetic counselling, clinical management and the use of targeted therapies, and potentially benefits patients globally.
科研通智能强力驱动
Strongly Powered by AbleSci AI